Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that cannot be removed by surgery
- Your cancer has an uncommon EGFR mutation (not the common ones like 19del, L858R, or T790M)
- You have not had any prior cancer treatment for this stage of your lung cancer
- You are age 18 or older and in generally good health (ECOG score 0 or 1)
- You do not have other serious health problems like uncontrolled infection, heart issues, or lung scarring
- You are able to swallow pills and attend follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called firmonertinib against standard EGFR inhibitor pills for people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations. It aims to see if firmonertinib works better in stopping the cancer from growing.
This trial tests a new targeted pill (Firmonertinib) combined with standard chemotherapy for stage III lung cancer that cannot be removed by surgery. It is for people with a specific EGFR mutation, and the goal is to see if the combo helps shrink or control the cancer.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
Hear when a new NSCLC (Non-small Cell Lung Carcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.